Investment accelerates global adoption of Noxilizer’s terminal sterilization alternative that is validated, safe, scalable and sustainable for biopharmaceutical and medical device manufacturers
HANOVER, Md., Sept. 10, 2025 /PRNewswire/ — Noxilizer, Inc. (“Noxilizer”), the leader in nitrogen dioxide-based terminal sterilization for biopharmaceutical and medical device products, today announced a growth capital financing of $30 million led by NewVale Capital, a growth equity firm focused on the pharmaceutical services sector.
Noxilizer’s nitrogen dioxide (“NO₂”) sterilization platform plays a pivotal role in addressing the urgent market demand for alternatives to ethylene oxide (“EtO”), with leading pharmaceutical, biotechnology, and medical device companies already relying on Noxilizer to sterilize critical drug-device combination products. This growth financing will expand access to Noxilizer’s NO₂ sterilization platform to meet growing global demand.
“This investment allows us to broaden availability of NO₂ sterilization at a time when manufacturers urgently need validated, commercial-ready alternatives to existing methods,” said Christopher Thatcher, President and Chief Executive Officer of Noxilizer. “We’re proud to provide a platform that is already trusted in commercial-stage products. With NewVale Capital’s support, we are strengthening our foundation to serve our customers at scale, with long-term reliability, especially as EtO contract sterilization providers face increasing remediation mandates and capacity constraints.”
Noxilizer provides biopharmaceutical and medical device manufacturers with a proven commercial-grade sterilization alternative that offers:
- Commercial and Regulatory Validation: Approved by global regulatory authorities and used in marketed biopharmaceutical products
- Safety and Sustainability: Non-carcinogenic with emissions that meet room air quality standards
- Compatibility: Works with sensitive biologics, drug-device combinations, and delivery systems
- Efficiency and Scale: Provides fast cycle times, can be used in-house, and supports supply chain reliability
“Noxilizer represents one of the most viable alternatives to EtO in the market today,” said Todd Holmes, Founder and Managing Partner of NewVale Capital. “The platform has already been adopted by a growing list of leading manufacturers, and we’re excited to support Noxilizer through its next phase of expansion to meet the rising demand for sustainable, next-generation sterilization.”
About Noxilizer
Noxilizer provides ultra-low temperature nitrogen dioxide (NO₂) terminal sterilization for the pharmaceutical, biotechnology, and medical device industries. With FDA approvals and clearance, EMA authorization, and adoption by leading global manufacturers, Noxilizer’s NO₂ sterilization is a safe, efficient, and scalable alternative to existing methods. The company offers R&D studies, packaging and design consulting, validation and customer and technical support in addition to its proprietary sterilization equipment and consumables. Noxilizer is headquartered in Hanover, Maryland. For more information, please visit: www.noxilizer.com.
About NewVale Capital
Founded in 2021, NewVale Capital is a growth equity investment firm focused on the services architecture underpinning the life science industry. The firm invests in proven, revenue-generating services businesses across the life science ecosystem that are helping to bring the next generation of medicines to patients. For more information, please visit: www.newvalecapital.com.
Media Contact:
Peg Rusconi
Senior Vice President, Media
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/noxilizer-expands-access-to-commercial-scale-nitrogen-dioxide-terminal-sterilization-capacity-with-30-million-in-growth-capital-led-by-newvale-capital-302551629.html
SOURCE Noxilizer, Inc.
